Business Context and Reporting Period
Connect Biopharma Holdings Limited, a foreign private issuer filing under Form 20-F, furnished this Form 6-K for November 2023. The report was dated November 1, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Change Versus Prior Period
On November 1, 2023, Nasdaq notified the Company that it had regained compliance with the minimum bid price requirement and that the matter was closed.
- Nasdaq had notified the Company on September 11, 2023 that its American Depositary Shares had traded below the required minimum bid price of $1.00 for 30 consecutive business days.
- The Company regained compliance after its ADSs maintained a minimum closing bid price of at least $1.00 for 10 consecutive trading days through October 31, 2023.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The principal disclosed issue was the previously identified Nasdaq listing deficiency, which has been resolved. Future compliance with Nasdaq listing standards remains an item investors may monitor.
The report states that it is incorporated by reference into the Company’s Form F-3 and Form S-8 registration statements, to the extent not superseded by later filings.
Investor Verification Items
- Verify the Company’s continued compliance with Nasdaq minimum bid price and other applicable listing requirements.
- Review subsequent SEC filings for financial results, cash runway, financing activity, and operating developments, which are not included in this Form 6-K.
- Consider the potential effect of the filing’s incorporation by reference on the Company’s existing registration statements.